PDF(Pubmed)
Abstract：
Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs.
摘要：
尽管心血管疾病是世界范围内死亡的主要原因，他们的药物治疗仍然不够理想。因此，开发更有效和更安全的药理学策略显然没有得到满足.在这次审查中,我们总结了2023年心血管药理学最相关的进展,包括批准了一流药物,为动脉粥样硬化性心血管疾病和心力衰竭的治疗开辟了新的途径.已上市的治疗梗阻性肥厚型心肌病的新适应症(再利用),高胆固醇血症,2型糖尿病,肥胖和心力衰竭，强调了多重用药对指南指导用药的影响以及阴性临床试验的结果.最后,最后，我们总结了最重要的2期和3期临床试验，这些临床试验评估了正在开发的用于预防和治疗心血管疾病的心血管药物的有效性和安全性。
